Dimerix Limited

DXB

AU000000DXB7

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 09:51:20 27/05/2024 am IST			5-day change	1st Jan Change
0.415 ^AUD	+22.06%		+16.90%	+102.44%

01/05	Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication	MT
22/04	Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter	MT

Dimerix Announces the Resignation of Elizabeth Jazwinska as Director

November 03, 2016 at 02:16 pm IST

Dimerix announced the resignation of Dr. Elizabeth Jazwinska as a director, effective immediately.

Latest news about Dimerix Limited

Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication	01/05	MT
Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter	23/04	MT
Euroz Hartleys Starts Dimerix at Speculative Buy With AU$0.80 Price Target	19/04	MT
Dimerix Raises AU$20 Million for Kidney Disease Study	12/03	MT
Dimerix Expanding Kidney Drug Study After DMX-200 Performs Better than Placebo	11/03	MT
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2023	26/02	CI
Dimerix Limited Announces Appointment of Mark Diamond as Director	01/12	CI
Dimerix Secures Investigational New Drug Approval for Kidney Disease Medication in China; Shares Rally 11%	28/11	MT
Dimerix Appoints Nonexecutive Chair	20/11	MT
Dimerix Receives AU$10.7 Million Upfront Payment for Commercialization Rights	07/11	MT
Dimerix Appoints Medical Chief	23/23/23	MT
Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer	23/23/23	CI
Softer US Employment Data End Australian Shares' Three-Day Losing Streak	05/23/05	MT
Dimerix Surges 154% After Securing License Deal for Kidney Disease Drug	05/23/05	MT
Dimerix Secures Conditional US FDA Clearance for Kidney Medication Brand Name	25/23/25	MT
Dimerix Secures Regulatory Nod to Conduct Kidney Disease Drug Trial in Malaysia	22/23/22	MT
Dimerix Secures AU$9 Million R&D Tax Rebate; Shares Rise 3%	13/23/13	MT
Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/23/30	CI
Dimerix Secures Approval for Pediatric Kidney Disease Plan in Europe	05/23/05	MT
Dimerix Secures Study Design Approval in China for Phase Three Kidney Disease Trial; Shares Rise 6%	03/23/03	MT
Dimerix Raising AU$12 Million to Continue Clinical Program; Shares Down 7%	04/23/04	MT
Dimerix Limited Appoints Clinton Snow New Non-Executive Director to the Board, Effective 01 May 2023	01/23/01	CI
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2022	27/23/27	CI
Dimerix Secures AU$2.8 Million in Prepayment of R&D Tax Rebate; Shares Rise 8%	17/23/17	MT
Dimerix Secures Safety Approval for Phase 3 Kidney Drug Trial	09/23/09	MT

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. It develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The Company is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets.

Sector

Biotechnology & Medical Research

Calendar

27/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DIMERIX LIMITED	+102.44%	124M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B